Renzhi Pei

Dr. Renzhi Pei


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YLYouhong Li
Youhong Li
MZMengting Zhao
Mengting Zhao
YLYe Lin
Ye Lin
XJXia Jiang
Xia Jiang
LJLili Jin
Lili Jin
LJLei Jiang
Lei Jiang

1 February 2024 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
XLXi Liu
Xi Liu
HZHaihui Zhuang
Haihui Zhuang
FLFenglin Li
Fenglin Li
YLYing Lu
Ying Lu
RPRenzhi Pei
Renzhi Pei
Background: Recently, an increasing number of studies have suggested dual-specificity phosphatase 23 (DUSP23) is a critical factor in the development of diffuse connective tissue disease and may be a valuable biomarker for primary human cancers. However, there is a lack of comprehensive studies on the prognostic significance of DUSP23 expression in acute myeloid leukemia (AML). Methods: RNA sequencing data from The Cancer Genome Atlas (TCGA) (AML = 173), Genotype-Tissue Expression (GTEx) (healthy controls = 70) and GEO (AML = 461, healthy controls = 76) databases were used to compare DUSP23 expression between AML patients and healthy controls. The overall survival (OS) of DUSP23 in AML was evaluated using Kaplan-Meier Cox regression. Furthermore, univariate Cox regression and multivariate Cox regression analysis were used to determine whether DUSP23 was an independent prognostic factor for AML. We then verified the expression level and prognostic significance of DUSP23 in our cohort (AML = 128, healthy controls = 31). In addition, functional enrichment analysis of DUSP23-related DEGs was performed through gene set enrichment analysis (GSEA) and protein-protein interaction (PPI) network analysis. Results: The expression level of DUSP23 is significantly higher in AML patients than in healthy controls in TCGA, GTEx, GEO databases and our cohort. By multivariate analysis, high expression of DUSP23 is a poor prognostic indicator of OS in the TCGA database. Next, we verified the role of DUSP23 as an adverse prognostic biomarker in our cohort. Enrichment analysis of related genes showed that DUSP23 may regulate important signal pathways in hematological tumors including the MAPK pathways. It is suggested by the PPI network that DUSP23, along with IMP3, MRPL4, MRPS12, POLR2L, and ATP5F1D may play a role in the process of AML. Conclusion: The study demonstrated high expression of DUSP23 could serve as a poor independent prognostic biomarker in AML.

19 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XLXi Liu
Xi Liu
HZHaihui Zhuang
Haihui Zhuang
FLFenglin Li
Fenglin Li
MSMinli Shen
Minli Shen
YLYing Lu
Ying Lu
RPRenzhi Pei
Renzhi Pei
The objective is to examine the data from the global burden of disease (GBD) 2021 to report on the global, regional, and national trends and rates related to the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for multiple myeloma in adults aged 40 and above. Data from the GBD 2021 was used in this study to evaluate the rates of incidence, prevalence, mortality, and DALYs related to multiple myeloma across global, regional, and national scales. To analyze these trends, joinpoint regression was applied to calculate the average annual percentage changes (AAPC). Further, the analysis was divided according to age, gender, region, and socio-demographic index (SDI). Projections extending to 2044 were also generated using the Nordpred model. From 1990 to 2021, an upward trend has been observed globally in the incidence, prevalence, mortality, and DALYs of multiple myeloma among adults aged 40 and older, with average annual percentage changes (AAPCs) of 0.53 (95% CI 0.41–0.64), 1.2 (95% CI 1.07–1.33), 0.19 (95% CI 0.07–0.31), and 0.15 (95% CI 0.04–0.26), respectively. Notably, middle SDI countries exhibited the most accelerated disease progression, demonstrating a 2.34 (95% CI 2.19–2.48) annual increase in age-standardized incidence rate (ASIR)—over fourfold higher than the global average. The increasing global burden of multiple myeloma in adults aged 40 and older, especially in areas and nations with lower SDI levels, underscores the pressing requirement for customized public health initiatives and policies to tackle this escalating issue.

1 November 2021 in Leukemia Research
Verified
Journal Article
Closed access
STShanhao Tang
Shanhao Tang
YLYin Lu
Yin Lu
PZPisheng Zhang
Pisheng Zhang
DCDong Chen
Dong Chen
XLXuhui Liu
Xuhui Liu
RPRenzhi Pei
Renzhi Pei

25 October 2024 in Acta Haematologica
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
XZXianxu Zhuang
Xianxu Zhuang
DLDanjie Luo
Danjie Luo
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
XLXuhui Liu
Xuhui Liu
Introduction: The combination of venetoclax (VEN) and azacytidine (AZA) has demonstrated potential in achieving rapid and effective remissions in elderly patients with acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation is a promising potential cure for high-risk AML, as VEN-based therapies have a worse prognosis in elderly patients. This study aimed to assess the efficacy of sequential haploidentical HSCT following two courses of VEN and AZA therapy in patients with AML aged 55 years and older. Methods: We conducted a retrospective study on AML patients aged 55–70 years who received intensive chemotherapy or two courses of VEN/AZA therapy, followed by haploidentical allo-HSCT (haplo-HSCT) based on disease risk degree, measurable residual disease status, and patient’s preference. Results: Between January 2019 and December 2023, 141 newly diagnosed AML patients received initial treatment with intensive chemotherapy or VEN/AZA therapy. Among them, 64 patients received haplo-HSCT, while 77 did not. The 1-year overall survival (OS) and relapse-free survival (RFS) of patients who received haplo-HSCT were significantly higher than those who did not receive haplo-HSCT (p < 0.05). Among patients who received transplantation, there was no significant difference in 1-year OS and RFS between the VEN/AZA and intensive chemotherapy groups: 76.3% versus 69.3% (p = 0.367) for OS, and 74.5% versus 69.7% (p = 0.473) for RFS. High-risk ELN stratification and the presence of ≥4 gene mutations were associated with lower OS and RFS in both univariate and multivariate analyses. Conclusions: AML patients over 55 years of age who received haplo-HSCT after two courses of VEN/AZA therapy had outcomes similar to those who received haplo-HSCT after intensive chemotherapy, suggesting that two courses of VEN/AZA therapy as a bridge to haplo-HSCT are feasible for patients over 55 years old.

24 March 2008 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
RPRenzhi Pei
Renzhi Pei
JMJ X Ma
J X Ma
PZP S Zhang
P S Zhang
XLX H Liu
X H Liu
JCJ J Cao
J J Cao
XDX H Du
X H Du